Education
About Us
Working with TipRanks
Follow Us
Immunicum AB (SE:IMMU)
:IMMU
Top Page
Immunicum AB
(Frankfurt:IMMU)
Rating:44Neutral
Price Target:
kr5.50
▲(3.58%Upside)
Immunicum AB (IMMU) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
€267.41M
Dividend YieldN/A
Average Volume (3M)20.86K
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue GrowthN/A
EPS Growth21.85%
CountrySE
Employees28
SectorHealthcare
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.60
Shares Outstanding50,359,577
10 Day Avg. Volume21,708
30 Day Avg. Volume20,864
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)0.58
Price to Sales (P/S)0.00
P/FCF Ratio-4.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Immunicum AB Business Overview & Revenue Model
Company DescriptionImmunicum AB is a biotechnology company focused on developing novel immune therapies for the treatment of various cancer types. The company operates within the life sciences sector and is dedicated to leveraging its proprietary technology platforms to create innovative solutions that enhance the body's ability to recognize and combat cancer. Its core product offerings are centered around allogeneic dendritic cell-based therapies aimed at improving patient outcomes in oncology.
How the Company Makes MoneyImmunicum AB generates revenue through the development and commercialization of its proprietary immune therapies. The company's primary revenue stream comes from partnerships and collaborations with larger pharmaceutical and biotechnology firms that are interested in co-developing or licensing its technology. These partnerships often involve milestone payments and royalties based on the success and commercialization of the therapies. Additionally, Immunicum may receive funding from grants or governmental support for innovative research in immuno-oncology. The company’s revenue model is heavily reliant on the successful progression of its therapies through clinical trials and subsequent market approval.
Immunicum AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 3.41M | 28.49M | 3.00M | 6.00K | 0.00 | 16.67M | Gross Profit |
| 1.79M | 28.49M | -1.85M | -1.84M | -1.77M | 15.03M | EBIT |
| -133.34M | -100.65M | -133.68M | -130.10M | -86.03M | -132.32M | EBITDA |
| -120.68M | -97.85M | -128.67M | -128.28M | -84.25M | -43.22M | Net Income Common Stockholders |
| -128.40M | -101.62M | -136.99M | -136.69M | -92.47M | -135.71M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 393.36M | 120.78M | 41.85M | 155.31M | 167.64M | 296.81M | Total Assets |
| 398.55M | 755.95M | 620.39M | 720.98M | 728.66M | 303.83M | Total Debt |
| 850.00K | 24.49M | 78.16M | 36.98M | 35.04M | 850.00K | Net Debt |
| -392.51M | -96.29M | 36.31M | -118.34M | -132.60M | -295.96M | Total Liabilities |
| 21.65M | 51.23M | 105.95M | 64.24M | 67.57M | 31.05M | Stockholders Equity |
| 376.90M | 704.73M | 514.44M | 656.74M | 661.09M | 272.78M |
| Cash Flow | Free Cash Flow | ||||
| -81.51M | -164.58M | -121.43M | -139.39M | -57.09M | -146.62M | Operating Cash Flow |
| -79.67M | -162.76M | -109.33M | -138.03M | -56.63M | -145.81M | Investing Cash Flow |
| -1.58M | -442.00K | -12.32M | -1.36M | 157.30M | -251.00K | Financing Cash Flow |
| 61.51M | 242.10M | 8.19M | 127.03M | 50.90M | 756.00K |
Immunicum AB Technical Analysis
Positive
5.31
Price Trends
5.41
Negative
6.54
Negative
7.60
Negative
Market Momentum
-0.06
Negative
50.02
Neutral
75.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IMMU, the sentiment is Positive. The current price of 5.31 is above the 20-day moving average (MA) of 5.25, below the 50-day MA of 5.41, and below the 200-day MA of 7.60, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 50.02 is Neutral, neither overbought nor oversold. The STOCH value of 75.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IMMU.
Immunicum AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
48 Neutral | kr379.37M | ― | -47.73% | ― | 45.52% | 93.35% | |
44 Neutral | €267.41M | ― | -18.79% | ― | ― | 21.85% | |
43 Neutral | €305.60M | ― | ― | 5303.85% | 55.59% | ||
42 Neutral | kr367.40M | ― | -24.61% | ― | 47.06% | 33.86% | |
36 Underperform | €185.74M | ― | -54.29% | ― | -100.00% | -17.35% | |
32 Underperform | kr375.12M | ― | -205.65% | ― | ― | 24.25% |
* Healthcare Sector Average
Performance Comparison
SE:IMMU
Immunicum AB
5.31
-4.28
-44.63%
SE:GUARD
Guard Therapeutics International AB
18.60
-15.54
-45.52%
SE:ISOFOL
Isofol Medical AB
1.15
0.43
60.17%
SE:IVACC
Intervacc AB
1.08
-1.79
-62.37%
SE:XBRANE
Xbrane Biopharma AB
0.25
-0.06
-19.81%
SE:XINT
Xintela AB
0.46
0.20
77.91%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.